McKesson (NYSE:MCK – Get Free Report) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $31.25-$32.05 for the period, compared to the consensus EPS estimate of $31.09. The company issued revenue guidance of $355.35-$361.53 billion, compared to the consensus revenue estimate of $341.05 billion.
McKesson Stock Performance
McKesson stock traded up $11.12 during trading hours on Tuesday, hitting $544.53. 983,843 shares of the stock were exchanged, compared to its average volume of 705,665. The business’s 50-day moving average is $531.17 and its two-hundred day moving average is $493.81. McKesson has a 12 month low of $364.08 and a 12 month high of $546.63. The stock has a market capitalization of $71.56 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.41 and a beta of 0.45.
McKesson (NYSE:MCK – Get Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.05 by $0.69. The firm had revenue of $80.90 billion for the quarter, compared to analysts’ expectations of $77.93 billion. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period last year, the firm earned $6.90 earnings per share. On average, equities analysts predict that McKesson will post 27.59 earnings per share for the current fiscal year.
McKesson Dividend Announcement
Wall Street Analysts Forecast Growth
MCK has been the topic of a number of research reports. SVB Leerink initiated coverage on McKesson in a research report on Monday, February 26th. They set an outperform rating and a $600.00 price objective on the stock. UBS Group lifted their target price on shares of McKesson from $575.00 to $620.00 and gave the stock a buy rating in a research note on Wednesday, March 6th. Citigroup upped their price target on shares of McKesson from $575.00 to $620.00 and gave the company a buy rating in a research report on Tuesday, April 30th. StockNews.com raised McKesson from a buy rating to a strong-buy rating in a research report on Saturday. Finally, Morgan Stanley upped their target price on McKesson from $522.00 to $548.00 and gave the company an overweight rating in a research report on Monday, April 15th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, McKesson currently has an average rating of Moderate Buy and a consensus price target of $536.71.
Read Our Latest Stock Analysis on McKesson
Insiders Place Their Bets
In other McKesson news, EVP Leann B. Smith sold 186 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the transaction, the executive vice president now owns 1,511 shares of the company’s stock, valued at $749,456. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the transaction, the chief executive officer now owns 43,445 shares in the company, valued at $22,789,074.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Leann B. Smith sold 186 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the sale, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by insiders.
McKesson Company Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Further Reading
- Five stocks we like better than McKesson
- Insider Trading – What You Need to Know
- Garmin Navigates to New Highs Driven By Wearables Trend
- Are Penny Stocks a Good Fit for Your Portfolio?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What are earnings reports?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.